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Background: Controversies are common in medicine. Some arise when the conclusions of research publications
directly contradict each other, creating uncertainty for frontline clinicians.
Discussion: In this paper, we review how researchers can look at very similar data yet have completely different
conclusions based purely on an over-reliance of statistical significance and an unclear understanding of confidence
intervals. The dogmatic adherence to statistical significant thresholds can lead authors to write dichotomized abso-
lute conclusions while ignoring the broader interpretations of very consistent findings. We describe three examples
of controversy around the potential benefit of a medication, a comparison between new medications, and a medi-
cation with a potential harm. The examples include the highest levels of evidence, both meta-analyses and random-
ized controlled trials. We will show how in each case the confidence intervals and point estimates were very similar.
The only identifiable differences to account for the contrasting conclusions arise from the serendipitous finding of
confidence intervals that either marginally cross or just fail to cross the line of statistical significance.
Summary: These opposing conclusions are false disagreements that create unnecessary clinical uncertainty. We
provide helpful recommendations in approaching conflicting conclusions when they are associated with remarkably
similar results.
Keywords: Confidence intervals, Evidence based medicine, Statistical analysis, Statistical significanceBackground
Most published reports of clinical studies begin with an
abstract – likely the first and perhaps only thing many
clinicians, the media and patients will read. Within that
abstract, authors/investigators typically provide a brief
summary of the results and a 1–2 sentence conclusion.
At times, the conclusion of one study will be different,
even diametrically opposed, to another despite the au-
thors looking at similar data. In these cases, readers may
assume that these individual authors somehow found
dramatically different results. While these reported differ-
ences may be true some of the time, radically diverse con-
clusions and ensuing controversies may simply be due to
tiny differences in confidence intervals combined with an
over-reliance and misunderstanding of a “statistically sig-
nificant difference.” Unfortunately, this misunderstanding
can lead to therapeutic uncertainty for front-line clinicians* Correspondence: michael.allan@ualberta.ca
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distribution, and reproduction in any mediumwhen in fact the overall data on a particular issue is re-
markably consistent.
A key concept of science is the formulation of hypoth-
eses and the testing these hypotheses by observing a set of
data. Typically in medicine one starts with an idea that a
therapy will have an effect. A statistical test assumes that
an intervention has no effect and this is called the null hy-
pothesis. A statistical evaluation simply provides informa-
tion as to how likely that the finding of a particular
difference could be due to chance and if there really was
no difference between the treatment groups.
We can NEVER prove a null hypothesis, meaning the
intervention has absolutely no effect. However, we de-
sign clinical studies with the hope they will provide in-
formation to help decide if we should reject or fail to
reject the null hypothesis. Rejecting the null hypothesis
is often interpreted to mean the intervention has an ef-
fect; failing to reject the null hypothesis is interpreted to
mean the intervention does not have an effect. These
simplistic interpretations ignore important factors suchntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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statistical power.
A well-designed randomized controlled trial (RCT) is
usually the least biased way to evaluate the difference
between different therapeutic interventions. Unless an
RCT has studied the entire population of interest, the
observed difference or ratio that is found is called a
point estimate because only a small sample of the entire
population has been evaluated. A point estimate is ty-
pically presented with a 95% (or less commonly 99%)
confidence interval (CI). A CI, while it has other inter-
pretations, can be thought of as a range of numeric out-
comes that we are reasonably confident includes the
actual result.
The choice of a specific CI typically comes from the
convention of a p-value of 0.05 representing a statistical
significance. This threshold has been discussed as being
arbitrary but has also been suggested to represent a rea-
sonable threshold [1]. Any statistical threshold can be
debated because a threshold depends on how comfort-
able one is that the results of a particular study may be
due to chance. However, what cannot be debated is that
this threshold was never developed to allow researchers
or clinicians to make dichotomous conclusions that, if a
p-value is greater than 0.05, the intervention has no ef-
fect and, if a p-value is less than 0.05, the intervention
has an effect. When using CIs to assess statistical signifi-
cance, the “no effect” cut-off occurs when the CI touches
the line of 1 for relative risks or odds ratios, and 0 for
absolute risks and weighted mean differences.
We have chosen three examples of this problem – a po-
tential benefit of a medication, a comparison between new
medications, and a medication with a potential harm. We
will show this problem occurs with the highest-level evi-
dence – randomized controlled trials and meta-analyses.
We have framed these into three clinical questions:
1) In patients without a history of cardiovascular
disease, do statins reduce mortality?
2) In patients with atrial fibrillation, when compared to
warfarin, is apixaban more effective than dabigatran
at reducing mortality?
3) In patients who smoke, does the use of varenicline
increase the risk of serious cardiovascular adverse
events?
Statins
Example 1. In patients without a history of cardiovascular
disease, do statins reduce mortality?
Statins are widely used in patients with and without estab-
lished cardiovascular disease. An important clinically rele-
vant question is: do statins have an effect on overall
mortality in patients who have not experienced a cardio-
vascular event? Because of the relatively low baseline 5-year risk of mortality in this population (roughly 5% over
5 years), no single study has been powered sufficiently to
provide a clear answer. For that reason, at least five differ-
ent meta-analyses examining this question have been pub-
lished [2-6].
The authors of these meta-analyses concluded the
following:
 Studer et al.: “statins and n-3 fatty acids are the
most favorable lipid-lowering interventions with re-
duced risks of overall and cardiac mortality.” [2]
 Thavendiranathan et al.: “statin therapy decreases
the incidence of major coronary and cerebrovascular
events and revascularizations but not coronary heart
disease or overall mortality.” [3]
 Mills et al.: “We examined the impact of statin
therapy on major events and found an important
role in preventing all-cause mortality” [4] although
this quote was not found in the abstract but rather
the first line of the discussion.
 Brugts et al.: “statin use was associated with
significantly improved survival.” [5]
 Ray et al.: “this literature-based meta-analysis did
not find evidence for the benefit of statin therapy on
all-cause mortality.” [6]
Three groups of investigators felt they had found the
pooled clinical trial evidence sufficient to state that sta-
tins reduce overall mortality; yet two others felt their
evidence did not support statins reducing overall mortal-
ity. Figure 1 shows the characteristics and overall mor-
tality relative risks of the five meta-analyses. Although
the different meta-analyses included some different stud-
ies, overall the investigators used similar data and, not
surprisingly, found similar results. The range of point es-
timates was 0.86 to 0.93 with an average point estimate
of 0.90. The lower limits of the CIs ranged from 0.76 to
0.83 and the upper limits ranged from 0.96-1.01. The
CIs overlap considerably and there is little meaningful
difference in the results. The only “differences” lie in
three meta-analyses [2,4,5] in which the upper limits of
the CI fell just below 1.0 and just above 1.0 in the other
two [3,6]. It appears the differing conclusions were due
solely to a proclivity for a p-value of 0.05 and adherence
to statistical significance as a dichotomous outcome.
Novel oral anticoagulants
Example 2. In patients with atrial fibrillation, when
compared to warfarin, is apixaban more effective than
dabigatran at reducing mortality?
A new class of oral anticoagulants (OACs) has recently
been released on the market. An important clinical ques-
tion is which one of these new agents is the most effective;





Mills 2008 19 (63,899) 0.93 (0.87 – 0.99)
Ray 2010 11 (65,229) 0.91 (0.83 – 1.01)
0.65 0.7 0.75 0.8 0.85 0.90 0.95 1 1.05 1.10.6
Number of Trials in Meta-analysis
(Number of Patients)
Brugts 2009 9 (67,476) 0.88 (0.81 – 0.96)
Thavendiranathan 2006 6 (39,937) 0.92 (0.84 – 1.01)
Studer 2005 9 (26,641) 0.86 (0.76 – 0.99)
Figure 1 Comparison of 5 meta-analyses examining relative risk of overall mortality with statin use in primary prevention. Footnote:
Brugts 2009 point estimate and confidence intervals are odds ratios (not relative risks).
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the new OACs and warfarin [7,8].
Connolly et al. state “The mortality rate was 4.13% per
year in the warfarin group, as compared with 3.75%
per year with 110 mg of dabigatran (P = 0.13) and 3.64%
per year with 150 mg of dabigatran (P = 0.051)” [7]. The
authors do not make any specific conclusions on mortal-
ity differences between warfarin and dabigatran.
In contrast, Granger et al. (ARISTOTLE) concluded
that “apixaban was superior to warfarin in preventing
stroke or systemic embolism, caused less bleeding, and
resulted in lower mortality” [8]. Interestingly, the press
stated: “ARISTOTLE: A major win for apixaban in
AF”, “the most positive yet” and “first of the three newStudy
(95%
Medication
Granger 2011 Apixaban 0
110 mg dabigatran 0
150 mg dabigatran 0
Connolly 2009
Figure 2 Comparison of 2 randomized controlled trials examining the
versus warfarin in atrial fibrillation.oral anticoagulants to show a clearly significant reduc-
tion in all-cause mortality.” [9]
Figure 2 shows the relative risk for mortality with each
drug (and dose) compared to warfarin. For all intent
purposes the results are basically identical, particularly
when comparing dabigatran 150 mg and apixaban.
The Granger paper [8] illustrates the importance that
authors attach whether or not results cross the magical
line of 1.0 and statistically significance. In Table Two of
the article, the authors present 10 outcome results –for
9 they include the upper limit of the CIs with numbers
to two decimal points. Yet for the mortality data, they
show the upper limit number to 3 decimal points (0.80-








relative risk of overall mortality with 2 novel oral anticoagulants
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rounded down to 0.99 rather than the more correct
rounding up to 1.00.
Varenicline
Example 3. In patients who smoke, does the use of
varenicline increase the risk of serious cardiovascular
adverse events?
Varenicline is a new smoking cessation medication
that is widely used. As with most new medications, the
long-term or rare side effects are unknown. For that
reason investigators have conducted meta-analyses of
many small trials to try to identify any previously un-
known adverse effects. Two meta-analyses have exam-
ined a possible risk of serious cardiovascular events
with varenicline [10,11].
Singh et al. reported that “Our meta-analysis raises
safety concerns about the potential for an increased risk
of serious adverse cardiovascular events associated with
the use of varenicline.” [10]
In contrast a later meta-analysis by Prochaska et al.
reported that varenicline used for smoking cessation
produced “no significant increase in cardiovascular
serious adverse events associated with varenicline
use” [11]. These authors go on to state “The conse-
quence of inflated risk estimates, such as those from
Singh and colleagues’ meta-analysis concerning the
effect of varenicline on serious adverse events related
to cardiovascular disease, can be unnecessary public
alarm and real harm, since patients may discontinue
their drug treatment out of fear of adverse effects and
clinicians may recommend cessation treatments of re-
duced efficacy or discourage use of the drug treat-
ment altogether.” [11]
Figure 3 shows the characteristics and serious car-
diovascular event peto odds ratios of the two meta-
analyses. As with the previous examples, the two
results are quite consistent with each other. The only
apparent reason for the contradictory conclusions
about risk was that the lower limit of the CI fell just
below 1.0 in one meta-analysis, and was just above 1.0
in the other.Study Point Es
(95% Confiden 
Number of Trials in Meta-analysis
(Number of Patients)
Prochaska 2012 22 (9232) 1.58 (0.90
Singh 2011 14 (8216) 1.72 (1.09
Figure 3 Comparison of 2 meta-analyses examining peto odds ratio o
smoking cessation.Pragmatic interpretation of the included studies
Based on the evidence presented, we believe the fol-
lowing represents a reasonable and pragmatic interpretation
of the results and how a clinician might use the information.
Statins’ effect on overall mortality in primary prevention
If you were a betting person, you should bet that statins
likely reduce mortality in primary prevention. The aver-
age point estimate in these meta-analyses was around
0.90 or a 10% relative reduction [2-6]. The relative re-
duction may vary from 0 to 20% but 10% is a reasonable
approximation [2-6]. The baseline risk of mortality was
approximately 5% [2-6], so using the 10% risk reduction
gives a 0.5% absolute reduction. Therefore, we need to
treat 200 primary prevention patients for one extra per-
son to avoid death over 5 years. Conversely, 199 will not
get a benefit in changing their risk of mortality. The CI
also suggests the absolute reduction in risk could be as
high as 1% or as little as 0%. Given the results we can
confidently say it is very unlikely that statins increase
mortality. Bottom-line, statins seem to have roughly a 1
in 200 effect on overall mortality in primary prevention.
Novel anti-coagulants effect on overall mortality in atrial
fibrillation
The evidence does not suggest any differences between
apixaban and dabigatran and their effect on mortality
compared to warfarin. As with the statins, dabigatran
and apixaban likely do reduce mortality, approximately
10% with a CI of 0% to 20% [7,8]. The baseline death
rate on warfarin was roughly 4% per year [7,8] so the re-
duction in risk would be 0.4% although it could be as
high as 0.8% or low as 0%. Therefore, we need to treat
250 atrial fibrillation patients with apixaban or dabiga-
tran instead of warfarin for one extra person to avoid
death over 1 year. Conversely, 249 will not get a benefit
in changing their risk of mortality. (Note: baseline death
rates may vary considerably based on a specific CHADS
score but we are using the average from the clinical
trials included [7,8].) Based on the evidence, it is very
unlikely that dabigatran or apixaban increase mortality
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on overall mortality in one year in atrial fibrillation
patients.
Varenicline effect on serious cardiovascular outcomes
If you were a betting person, you should bet that vareni-
cline likely does increase the risk of cardiovascular
events. The point estimate was roughly 60-70% but the ef-
fect could be as high as a 176% increase or an actual 10%
reduction in cardiovascular events [10,11]. Importantly,
baseline cardiovascular risk can vary dramatically. A 30-
year-old female with no risk factors except smoking may
have 0.5% 5-year risk or a 0.1% one year risk of a cardio-
vascular event. If varenincline increased risk by 60%, one
extra cardiovascular event would occur for every 1667 pa-
tients treated. In patients immediately post-MI, whose
CVD risk may approach 5% in the first year, varenicline
may lead to one extra cardiovascular event for every 34
patients treated (7 of whom would quit smoking). In these
patients, the benefits may still outweigh risks but a discus-
sion around potential risks and options would be appropri-
ate. Bottom-line, varenicline likely produces an increased
risk of cardiovascular events but this risk may be <1/1000
for low risk patients to as much as in 1/34 for the highest
risk patients. However, the benefits of smoking cessation
are considerable.
Discussion
It appears that medical authors feel the need to make
black and white conclusions when their data almost
never allows for such dichotomous statements. This is
particularly true when comparing results to similar stud-
ies with largely overlapping CIs. Virtually all of the con-
clusion confusion discussed in this paper can be linked
to slavish adherence to an arbitrary threshold for statis-
tical significance. Even if the threshold is reasonable, it
still cannot be used to make dichotomous conclusions.
Although we have selected three examples here, these
are certainly not the only ones. In another example we
considered, the authors of two meta-analyses of primary
prevention with aspirin report the exact same point esti-
mate and confidence interval 0.94 (0.88-1.00) but had
differing conclusions [12,13]. We tried to select a small
but representative group of examples that would be fa-
miliar to most readers.
We are not the first authors to write about the misin-
terpretation of CIs and statistical significance. About 60
years ago, RA Fischer introduced the p-value for hypoth-
esis and significance testing [14]. Although 0.05 was sug-
gested as a reasonable indicator for significance, he did
assert the interpretation was open [14]. Over 30 years
ago, a number of articles were published encouraging me-
dical researchers to report their results with CIs [15-18].
CIs provide an estimation reflecting the potential range ofeffect rather than simply stating if results are statistically
significant or not [15-17]. Unfortunately, this goal fell short
as CIs are frequently used to define whether a result is or is
not statistically significant. In the 60 plus year history, arti-
cles on application of statistical reporting continue to en-
courage authors to present their findings [17,19,20], allow
readers to interpret results [14,17,19,20] and not use CIs
strictly for reporting statistical significance [17,20].
We encourage authors to avoid statements like “X has
no effect on mortality” as they are likely to be both un-
true and misleading. This is especially true as results get
“close” to being statistically significant. Results should
speak for themselves. For that to happen, readers (clini-
cians and science reporters) need to understand the lan-
guage of statistics and approach authors’ conclusions
with a critical eye. We are not trying to say that the
reader should not review the abstract but when authors’
conclusions differ from others, readers must examine
and compare the actual results. In fact, all but one of the
meta-analyses provided point estimates and CIs in the
abstracts. This facilitates quick comparisons to other
studies reported to be “completely different,” and to de-
termine if the CIs demonstrate clinically important dif-
ferences. The problem lies in the authors’ conclusions,
which often have little to do with their results but rather
what they want the results to show. We encourage jour-
nal editors to challenge authors’ conclusions, particularly
when they argue they have found something unique or
different than other researchers but the difference is
based solely on tiny variations in CIs or p-value (statisti-
cally significant or not).
We are not suggesting the elimination of statistical test-
ing or statistical significance, but rather that all people
(authors, publishers, regulators etc.) who write about
medical interventions use common sense and good judg-
ment when presenting results that differ from others and
not be so beholden to the “magical” statistical significance
level of 0.05. We urge them to consider the degree to
which the results of the “differing” study overlap with
their own, the true difference in the point estimates and
range of possible effects, where the preponderance of the
effect lies and how clinicians might apply the evidence.
It appears that readers of the papers discussed here
would be better served by reviewing the actual results
than reading the authors’ conclusions. To do that, clini-
cians need to be able to interpret the meaning of CIs
and statistical significance.
Summary
Dogmatic adherence to statistical significance thresholds
can lead authors to write dichotomized absolute conclu-
sions while ignoring the broader interpretations of very
consistent findings. These opposing conclusions are false
disagreements that create unnecessary clinical uncertainty.
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ally. Readers and clinicians are encouraged to compare
the actual data and precision of the results rather than
rely on the conclusions of the authors.
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